^
    Back
    Association details:
    Biomarker:SNX20 overexpression + PD-L1 overexpression
    Cancer:Lung Adenocarcinoma
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Onco Targets Ther
    Title:

    Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma

    Published date:
    10/09/2020
    Excerpt:
    High SNX20/high PD-L1 expression group had longer overall survival than patients with high SNX20/low PD-L1 expression...
    DOI:
    10.2147/OTT.S262909